Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
Dig into best practices for measuring the operational effectiveness of Medical Affairs teams, emphasizing the importance of establishing a strong foundation of data and metrics to demonstrate impact and value within pharmaceutical organizations.
In this webinar, we will share new data showing that while medical affairs is increasing in importance, it is still struggling to reach a consensus around medical impact metrics. However, measuring medical impact is no longer a choice; it’s a necessity for medical to communicate its value as a business function and better demonstrate its contributions to successful patient outcomes.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.
Experts from Lumanity discuss cross-functional alignment of Integrated Evidence Generation Planning (IEGP) from perspectives of strategy, clinical/regulatory, commercial and patient engagement.
Determining the most effective medical or commercial strategy requires measuring what’s happening in the market via a strong insights management process. Powering your insights process with different data sources (such as social media and other online conversations, medical information, congresses, advisory boards, and field observations) is critical for a full 360-degree view of the market.
In this discussion, you’ll learn:
This series of the Elevate Podcast illuminates the Inspiration and Impact, content Compliance & Approval, MSL utilization, Training & Evolution, the Technology Stack, and the Future of Modular Content.
From the Spreadsheet Age to the Age of Generative AI: Where is your organization on the continuum of Insights Management? (And why no one “age” fits the needs of all teams.)
As the sources of data and technologies needed to make sense of data expand, opportunities exist for further integrating RWE and HEOR alongside traditional approaches when planning data generation activities to support new product registration, access, and use.
Getting the most impact from a publication requires being able to define who the audience is and how to reach them, across both journals and online channels, especially in complex/niche cases. In this podcast, we discuss the benefits of taking an analytical approach.